Macroamylasemia with a markedly increased amylase clearance ratio in patient with renal cell carcinoma

Steven (Steve) Kazmierczak, F. Van Lente, A. M. McHugh, W. E. Katzin

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We report hyperamylasemia, macroamylasemia, and a markedly increased amylase clearance/creatinine clearance ratio in a patient with renal cell carcinoma. Serum amylase activity was characterized as macroamylase by gel exclusion chromatography. Electrophoretic separation revealed an atypical band of amylase, migrating anodal to the S2 control fraction. Electrophoresis of urine revealed the prescence of both S1 and S2 fractions, but not the atypical band found in serum. Quantification of the salivary- and pancreatic-type amylase fractions showed amylase in urine to be 100% salivary. Immunofixation disclosed the macroamylase to consist of an immune complex between amylase and IgA-lambda antibody. Binding-capacity studies showed that the serum immunoglobulin was present in excess and could bind 46% and 49% additional S-type amylase activity derived from saliva and the patient's urine, respectively. The amylase clearance/creatinine clearance ratio was markedly supranormal (0.134), unexpected in a patient with macroamylasemia. A biopsy specimen of the renal cell tumor was found to contain significant salivary-type amylase activity. These results suggest production of amylase by tumor tissue in the renal carcinoma and secretion of S-type amylase into the patient's urine. Evidently, macroamylase should be confirmed by gel exclusion chromatography.

Original languageEnglish (US)
Pages (from-to)435-438
Number of pages4
JournalClinical Chemistry
Volume34
Issue number2
StatePublished - 1988
Externally publishedYes

Fingerprint

Hyperamylasemia
Amylases
Renal Cell Carcinoma
Cells
Gel Chromatography
Urine
Chromatography
Tumors
Creatinine
Gels
Serum
Kidney
Biopsy
Antigen-Antibody Complex
Electrophoresis
Saliva
Immunoglobulin A
Immunoglobulins
Neoplasms

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Macroamylasemia with a markedly increased amylase clearance ratio in patient with renal cell carcinoma. / Kazmierczak, Steven (Steve); Van Lente, F.; McHugh, A. M.; Katzin, W. E.

In: Clinical Chemistry, Vol. 34, No. 2, 1988, p. 435-438.

Research output: Contribution to journalArticle

@article{3cb6dc6adc28498c911406d6d2da6ca7,
title = "Macroamylasemia with a markedly increased amylase clearance ratio in patient with renal cell carcinoma",
abstract = "We report hyperamylasemia, macroamylasemia, and a markedly increased amylase clearance/creatinine clearance ratio in a patient with renal cell carcinoma. Serum amylase activity was characterized as macroamylase by gel exclusion chromatography. Electrophoretic separation revealed an atypical band of amylase, migrating anodal to the S2 control fraction. Electrophoresis of urine revealed the prescence of both S1 and S2 fractions, but not the atypical band found in serum. Quantification of the salivary- and pancreatic-type amylase fractions showed amylase in urine to be 100{\%} salivary. Immunofixation disclosed the macroamylase to consist of an immune complex between amylase and IgA-lambda antibody. Binding-capacity studies showed that the serum immunoglobulin was present in excess and could bind 46{\%} and 49{\%} additional S-type amylase activity derived from saliva and the patient's urine, respectively. The amylase clearance/creatinine clearance ratio was markedly supranormal (0.134), unexpected in a patient with macroamylasemia. A biopsy specimen of the renal cell tumor was found to contain significant salivary-type amylase activity. These results suggest production of amylase by tumor tissue in the renal carcinoma and secretion of S-type amylase into the patient's urine. Evidently, macroamylase should be confirmed by gel exclusion chromatography.",
author = "Kazmierczak, {Steven (Steve)} and {Van Lente}, F. and McHugh, {A. M.} and Katzin, {W. E.}",
year = "1988",
language = "English (US)",
volume = "34",
pages = "435--438",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "2",

}

TY - JOUR

T1 - Macroamylasemia with a markedly increased amylase clearance ratio in patient with renal cell carcinoma

AU - Kazmierczak, Steven (Steve)

AU - Van Lente, F.

AU - McHugh, A. M.

AU - Katzin, W. E.

PY - 1988

Y1 - 1988

N2 - We report hyperamylasemia, macroamylasemia, and a markedly increased amylase clearance/creatinine clearance ratio in a patient with renal cell carcinoma. Serum amylase activity was characterized as macroamylase by gel exclusion chromatography. Electrophoretic separation revealed an atypical band of amylase, migrating anodal to the S2 control fraction. Electrophoresis of urine revealed the prescence of both S1 and S2 fractions, but not the atypical band found in serum. Quantification of the salivary- and pancreatic-type amylase fractions showed amylase in urine to be 100% salivary. Immunofixation disclosed the macroamylase to consist of an immune complex between amylase and IgA-lambda antibody. Binding-capacity studies showed that the serum immunoglobulin was present in excess and could bind 46% and 49% additional S-type amylase activity derived from saliva and the patient's urine, respectively. The amylase clearance/creatinine clearance ratio was markedly supranormal (0.134), unexpected in a patient with macroamylasemia. A biopsy specimen of the renal cell tumor was found to contain significant salivary-type amylase activity. These results suggest production of amylase by tumor tissue in the renal carcinoma and secretion of S-type amylase into the patient's urine. Evidently, macroamylase should be confirmed by gel exclusion chromatography.

AB - We report hyperamylasemia, macroamylasemia, and a markedly increased amylase clearance/creatinine clearance ratio in a patient with renal cell carcinoma. Serum amylase activity was characterized as macroamylase by gel exclusion chromatography. Electrophoretic separation revealed an atypical band of amylase, migrating anodal to the S2 control fraction. Electrophoresis of urine revealed the prescence of both S1 and S2 fractions, but not the atypical band found in serum. Quantification of the salivary- and pancreatic-type amylase fractions showed amylase in urine to be 100% salivary. Immunofixation disclosed the macroamylase to consist of an immune complex between amylase and IgA-lambda antibody. Binding-capacity studies showed that the serum immunoglobulin was present in excess and could bind 46% and 49% additional S-type amylase activity derived from saliva and the patient's urine, respectively. The amylase clearance/creatinine clearance ratio was markedly supranormal (0.134), unexpected in a patient with macroamylasemia. A biopsy specimen of the renal cell tumor was found to contain significant salivary-type amylase activity. These results suggest production of amylase by tumor tissue in the renal carcinoma and secretion of S-type amylase into the patient's urine. Evidently, macroamylase should be confirmed by gel exclusion chromatography.

UR - http://www.scopus.com/inward/record.url?scp=0023846129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023846129&partnerID=8YFLogxK

M3 - Article

C2 - 2449303

AN - SCOPUS:0023846129

VL - 34

SP - 435

EP - 438

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 2

ER -